Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2024 05:39 ET | Source: Research and Markets

Acquired Orphan Blood Disease Market Research Reveals Rapid Growth in Asia and Innovative Therapies

Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Acquired Orphan Blood Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
June 06, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Myelodysplastic Syndrome Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market - AbbVie, Gilead Sciences, Novartis, AstraZeneca, Sanofi, Incyte, Celgene, Fibrogen, Precigen

New Year, USA, June 06, 2023 (GLOBE NEWSWIRE) -- Myelodysplastic Syndrome Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market - AbbVie, Gilead Sciences, Novartis,...
July 12, 2021 08:40 ET | Source: CMI

Myelodysplastic Syndrome Treatment Market in U.S., Europe, and China to Surpass US$ 3,404.1 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment market is estimated to be valued at US$ 2,042.6...
May 07, 2019 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update

Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in...
November 05, 2018 13:00 ET | Source: Lixte Biotechnology Holdings, Inc.

FDA Approves Lixte Biotechnology’s IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center

EAST SETAUKET, NY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the FDA approved its IND to conduct a Phase 1b/2 trial of the safety and...
October 09, 2018 09:45 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center

EAST SETAUKET, NY , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety...
August 21, 2018 09:45 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome

EAST SETAUKET, NY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement...
February 28, 2018 07:30 ET | Source: Actinium Pharmaceuticals

Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations

- Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received at the Company’s investigator meeting and by Iomab-B’s scientific advisory board - Product theater...
January 08, 2018 07:30 ET | Source: Actinium Pharmaceuticals

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs

- Dr. Ludwig brings over 20 years of leadership and management expertise from Eli Lilly and Company and Imclone Systems, Inc. in oncology antibody therapeutics discovery and development where he...
December 05, 2017 07:30 ET | Source: Actinium Pharmaceuticals

Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations

Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndromeTrial principal...

Next Page keyboard_arrow_right